B1 step ahead of mantle cell lymphoma (MCL)

Cofunding Core Facility - Patient-derived xenograft models

Targeting MEF2C in immature acute leukemias

Asparagine deprivation using a novel safer L-asparaginase to treat ovarian cancer

Doctoral project Evelien Peeters

Doctoral project Lasse Vleminckx

Drug response profiling of T-cell acute lymphoblastic leukemia to optimize salvage therapeutic strategies for refractory/relapsed patients

PROTACs to degrade oncogenic transcription factors in acute leukemia

Targeting the micro-environment in acute lymphoblastic leukemia

Targeting transcription factors addiction in acute leukemia

Clinical implementation of drug response profiling to improve survival rates in relapsed or refractory acute leukemia in children and adolescents

Doctoral project Bert Luyckx

An alternative more tolerable L-asparaginase variant for the treatment of metastatic breast cancer

A patient derived xenograft (PDX) platform for in vivo evaluation of novel anticancer therapies

BOF-TT-professorship in Haematology, Oncology, Immunology

CRISPR-cas9 targeting in T-ALL

Drug response profiling of T-cell acute lymphoblastic leukemia to optimize salvage therapeutic strategies for refractory/relapsed patients

Establishing safety and efficacy of an improved Asparaginase in dog models: final preparation for Phase I clinical trial

Oncogenic Role of SOX11 in T-cell acute lymphoblastic leukemia

Replication fork protector dependency factors: novel targets for combination treatment and immunomodulation in neuroblastoma (REINFORCE)

Role of TET2 in (pre)-leukemic T-ALL: TET2 to the rescue?

Targeting the amino acid stress response (AAR) pathway to treat triple negative breast cancers

Targeting the amino acid stress response pathway in aggressive cancer subtypes

Targeting transcription factor addiction in acute leukemia (TaTFAL)

TET2 to the rescue in T-ALL

The dual role PSIP1 in T-cell acute lymphoblastic leukemia (T-ALL)

The role of PSIP1 and Menin in T-cell acute lymphoblastic leukemia (T-ALL)

The use of a less toxic alternative asparaginase variant to treat metastatic breast cancer

Towards clinical testing of improved, less toxic and less immunogenic, L-asparaginase formulations for the treatment of ovarian cancer

Towards clinical testing of improved, less toxic and less immunogenic, L-asparaginase preparations for the treatment of acute lymphoblastic leukemia

Towards clinical testing of novel stabilized less toxic asparaginases for the treatment of acute lymphoblastic leukemia

Towards the global use of Asn deprivation to treat aggressive subtypes of cancer by using alternative, less immunogenic L-asparaginase variants with less toxic side-effects

Improved human iPS generation by targeting the reprogrammingsfactors in an inducible and exchangeable way within the human ROSA26 locus via ZFN

IVIS Lumina III LT In Vivo imaging system.

Molecular mechanisms controlling pre-leukemic stem cells in the thymus

Preclinical validation of a less toxic variant for paediatric leukemia

Role of ZEB2 in T-cell acute lymphoblastic leukemia (T-ALL) initiation and Progression

Targeting pathways involved in ZEB1-driven EMT in an aggressive subtype of colorectal cancer

BOF-TT-professorship in Haematology, Oncology, Immunology

Functional characterization of the EMT inducer, ZEB2/SIP1 during definitive hematopoiesis

Targeted immunotherapy for the treatment of T-cell acute lymphoblastic leukemia